Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,519.12
(
0.61%
)
US TECH 100
29,229.20
(
1.84%
)
Dow Jones
50,461.68
(
-0.23%
)
Brent Oil
94.78
(
-2.27%
)
Bitcoin
75,601.92
(
-0.32%
)
News Focus
News Focus
Post# of 257644
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123024
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Thursday, 01/31/2008 4:32:59 PM

Thursday, January 31, 2008 4:32:59 PM

Post# of 257644
BMY’s Sustiva for HIV is now officially a blockbuster: 4Q07 sales were $260M (a $1.04B annualized rate), +17% vs 4Q06.

Growth is coming almost entirely from increased demand for Atripla, the combination pill that includes Sustiva, Viread, and Emtriva.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today